Basilea Published P-III Study (ERADICATE) Results of Ceftobiprole for Staphylococcus Aureus Bacteremia in the NEJM
Shots:
- The P-III study evaluating ceftobiprole vs daptomycin in 390 adult patients with complicated SAB, incl. right-sided infective endocarditis at 60 sites in 17 countries
- The results showed that ceftobiprole was non-inferior to daptomycin with overall treatment success (69.8% vs 68.7%). The results were consistent in key subgroups, incl. patients with MRSA or methicillin-susceptible Staphylococcus aureus
- Clearance of MRSA & MSSA bacteria from the bloodstream (93.3% vs 87.8% after a median of 5 days) & 94.3% after a median of 3 days vs 95.2% of 4 days of treatment & the safety profile was consistent with prior P-III studies & post-marketing experience. Ceftobiprole received QIDP from the US FDA for SAB, ABSSSI & CABP
Ref: GlobalNewswire | Image: Basilea
Related News:- Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
